Autolus Therapeutics (NASDAQ:AUTL – Get Rating)‘s stock had its “buy” rating reiterated by Needham & Company LLC in a note issued to investors on Tuesday, Benzinga reports. They currently have a $7.00 target price on the stock. Needham & Company LLC’s price objective would indicate a potential upside of 243.14% from the stock’s previous close.
Separately, Mizuho decreased their target price on shares of Autolus Therapeutics from $18.00 to $12.00 and set a “buy” rating on the stock in a research report on Wednesday.
Autolus Therapeutics Price Performance
Shares of NASDAQ AUTL opened at $2.04 on Tuesday. The firm has a market capitalization of $353.04 million, a P/E ratio of -1.30 and a beta of 1.59. Autolus Therapeutics has a one year low of $1.60 and a one year high of $4.73. The company’s fifty day moving average is $1.95 and its two-hundred day moving average is $2.40. The company has a debt-to-equity ratio of 0.07, a quick ratio of 5.47 and a current ratio of 5.47.
Institutional Investors Weigh In On Autolus Therapeutics
Autolus Therapeutics Company Profile
Autolus Therapeutics Plc is a biopharmaceutical company, which engages in the development and commercialization of gene therapies. It uses proprietary and modular T cell programming technologies that are designed to recognize cancer cells, break down their defense mechanisms, and attack and kill these cells.
- Get a free copy of the StockNews.com research report on Autolus Therapeutics (AUTL)
- META Platforms May See its Biggest Opening Yet for New Highs
- Penny Stock Vinco Ventures Could Be Big Winner
- Is Chip Design Specialist Synopsys A Gem Hiding In Plain Sight?
- Should You Park Some Capital with Casey’s General Stores?
- Crowdstrike Stock: While The Iron Is Hot!
Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.